A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

PHASE2CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

May 4, 2005

Primary Completion Date

February 23, 2016

Study Completion Date

February 23, 2016

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Belimumab

Belimumab 10mg/kg IV over one hour every 28 days

Trial Locations (57)

11021

GSK Investigational Site, Great Neck

11030

GSK Investigational Site, Manhasset

11203

GSK Investigational Site, Brooklyn

12206

GSK Investigational Site, Albany

14618

GSK Investigational Site, Rochester

15217

GSK Investigational Site, Pittsburgh

19090

GSK Investigational Site, Willow Grove

20010

GSK Investigational Site, Washington D.C.

20902

GSK Investigational Site, Wheaton

21201

GSK Investigational Site, Baltimore

21287

GSK Investigational Site, Baltimore

21502

GSK Investigational Site, Cumberland

27157

GSK Investigational Site, Winston-Salem

28210

GSK Investigational Site, Charlotte

30303

GSK Investigational Site, Atlanta

33180

GSK Investigational Site, Aventura

33614

GSK Investigational Site, Tampa

35294

GSK Investigational Site, Birmingham

40202

GSK Investigational Site, Louisville

45417

GSK Investigational Site, Dayton

46321

GSK Investigational Site, Munster

53226

GSK Investigational Site, Milwaukee

54650

GSK Investigational Site, Onalaska

60611

GSK Investigational Site, Chicago

60612

GSK Investigational Site, Chicago

63110

GSK Investigational Site, St Louis

66160

GSK Investigational Site, Kansas City

68516

GSK Investigational Site, Lincoln

70121

GSK Investigational Site, New Orleans

70809

GSK Investigational Site, Baton Rouge

73103

GSK Investigational Site, Oklahoma City

73104

GSK Investigational Site, Oklahoma City

74104

GSK Investigational Site, Tulsa

75246

GSK Investigational Site, Dallas

77074

GSK Investigational Site, Houston

77479

GSK Investigational Site, Sugar Land

80920

GSK Investigational Site, Colorado Springs

83401

GSK Investigational Site, Idaho Falls

83704

GSK Investigational Site, Boise

85260

GSK Investigational Site, Scottsdale

85724

GSK Investigational Site, Tucson

90033

GSK Investigational Site, Los Angeles

90048

GSK Investigational Site, Los Angeles

91786

GSK Investigational Site, Upland

92037

GSK Investigational Site, La Jolla

95124

GSK Investigational Site, San Jose

95817

GSK Investigational Site, Sacramento

98133

GSK Investigational Site, Seattle

99204

GSK Investigational Site, Spokane

32806-6264

GSK Investigational Site, Orlando

02111

GSK Investigational Site, Boston

48109-5542

GSK Investigational Site, Ann Arbor

03301

GSK Investigational Site, Concord

03820

GSK Investigational Site, Dover

75390-8550

GSK Investigational Site, Dallas

22205-3606

GSK Investigational Site, Arlington

H3G 1A4

GSK Investigational Site, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Human Genome Sciences Inc., a GSK Company

INDUSTRY